Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilzabrutinib in moderate to severe pemphigus
NCT03762265Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Jan 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of rilzabrutinib in pemphigus vulgaris (PV), pemphigus foliaceus (PF), sponsored by Sanofi. Started Jan 2019; status: terminated.
02
Drugs
rilzabrutinib
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on NCT03762265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03762265.